Latest News
In partnership with BrightFocus Foundation, the Medical Technology Enterprise Consortium (MTEC) today announced a request for proposals for research that will enable the advancement of candidate drugs for the treatment of repeated mild traumatic brain injury (mTBI).
Inhibiting thyroid hormone (TH) activity helps protect against retinal degeneration in an animal model of AMD.
BrightFocus Foundation, a premier private funder of vision research, today announced a request for proposals for science projects supported through its National Glaucoma Research program.
Researchers unravel the reasons why some patients have no response or diminished response over time to anti-VEGF [vascular endothelial growth factor) drugs used to treat age-related macular degeneration (AMD) and discover an innovative and effective combination therapy.
BrightFocus Foundation announced a free virtual town hall to discuss the challenges currently facing caregivers across America and offer helpful advice to guide us through the coming months.
BrightFocus-funded projects get at the root of capillary stalling in Alzheimer’s disease, which reduces brain blood flow and increases risk for dementia. Evidence from mice suggests it’s not driven by diet and obesity alone, and a targeted treatment could help.
Early research shows one can prevent loss of brain nerve cell communication in Alzheimer’s disease by blocking ‘caspase’ from making toxic amyloid-beta from APP.
The top four food groups for eye health, COVID-19 and macular degeneration, the importance of regular eye exams, how to make the most of your eye doctor appointment, potential medications for dry macular degeneration. and more are discussed in the summer edition of Macular Degeneration News.
Toll-like receptor 2 (TLR2) is revealed to be a bridge between oxidative damage and inflammation in age-related macular degeneration.
BrightFocus Foundation, a leading nonprofit funder of global research on Alzheimer’s, macular degeneration, and glaucoma, today announced 93 new research grants, a $17.8 million commitment toward ending these age-related neurodegenerative diseases.